Brief: Immuron Seeks Trading Halt Pending Announcement On Phase 2 Imm-124E Clinical Trial Top-Line Results
March 5 (Reuters) - Immuron Ltd IMC.AX :
* SEEKS TRADING HALT PENDING ANNOUNCEMENT ON PHASE 2
IMM-124E
CLINICAL TRIAL TOP-LINE RESULTS
Further company coverage: IMC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immuron
See all newsBrief: Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives
Australia's Immuron hits near 1.5-month high on distribution deal in US
Brief: Immuron Executes Exclusive Distribution Agreement For Proibs In The United States
Brief: Immuron Reports FY26 Preliminary Results
Brief: Immuron Posts FY Revenue From Ordinary Activities Of A$7.71 Million